187 related articles for article (PubMed ID: 25761485)
1. Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism.
Lim SH; Woo SY; Kim S; Ko YH; Kim WS; Kim SJ
Cancer Res Treat; 2016 Jan; 48(1):312-21. PubMed ID: 25761485
[TBL] [Abstract][Full Text] [Related]
2. Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B-cell lymphoma.
Rupa-Matysek J; Gil L; Kroll-Balcerzak R; Barańska M; Komarnicki M
Hematol Oncol; 2017 Dec; 35(4):456-464. PubMed ID: 27377517
[TBL] [Abstract][Full Text] [Related]
3. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
4. Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma.
Borg IH; Bendtsen MD; Bøgsted M; Madsen J; Severinsen MT
Leuk Lymphoma; 2016 Dec; 57(12):2771-2776. PubMed ID: 27266904
[TBL] [Abstract][Full Text] [Related]
5. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score.
Rupa-Matysek J; Gil L; Kaźmierczak M; Barańska M; Komarnicki M
Med Oncol; 2017 Dec; 35(1):5. PubMed ID: 29209847
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
7. The Application of the ThroLy Risk Assessment Model to Predict Venous Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma.
Abdel-Razeq H; Ma'koseh M; Mansour A; Bater R; Amarin R; Abufara A; Halahleh K; Manassra M; Alrwashdeh M; Almomani M; Zmaily M
Clin Appl Thromb Hemost; 2021; 27():10760296211045908. PubMed ID: 34590497
[TBL] [Abstract][Full Text] [Related]
8. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.
Sun F; Zhu J; Lu S; Zhen Z; Wang J; Huang J; Ding Z; Zeng M; Sun X
BMC Cancer; 2018 Jan; 18(1):5. PubMed ID: 29291712
[TBL] [Abstract][Full Text] [Related]
9. Incidence of venous thromboembolism and predictive ability of age-adjusted international prognostic index for prediction of venous thromboembolism in Asian patients with diffuse large B-cell lymphoma.
Hantrakun N; Phinyo P; Tantiworawit A; Rattarittamrong E; Chai-Adisaksopha C; Rattanathammethee T; Hantrakool S; Piriyakhuntorn P; Punnachet T; Niprapan P; Norasetthada L
J Thromb Thrombolysis; 2024 Mar; 57(3):473-482. PubMed ID: 38091158
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors for developing venous thromboembolism in Japanese with diffuse large b-cell lymphoma.
Yokoyama K; Murata M; Ikeda Y; Okamoto S
Thromb Res; 2012 Jul; 130(1):7-11. PubMed ID: 22000981
[TBL] [Abstract][Full Text] [Related]
11. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
12. Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Park S; Han B; Cho JW; Woo SY; Kim S; Kim SJ; Kim WS
Nutr Cancer; 2014; 66(2):225-33. PubMed ID: 24405259
[TBL] [Abstract][Full Text] [Related]
13. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma.
Sanfilippo KM; Wang TF; Gage BF; Luo S; Riedell P; Carson KR
Thromb Res; 2016 Jul; 143():86-90. PubMed ID: 27208462
[TBL] [Abstract][Full Text] [Related]
14. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
Kwon J; Kim IH; Kim BH; Kim TM; Heo DS
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):91-8. PubMed ID: 25721091
[TBL] [Abstract][Full Text] [Related]
15. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
16. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
17. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Nakamura N; Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Sawada M; Yamada T; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2013 Oct; 91(4):322-31. PubMed ID: 23672298
[TBL] [Abstract][Full Text] [Related]
18. [Results of immuno-chemotherapeutic treatment of patients with diffuse large B-cell lymphoma].
Schneider T; Molnár Z; Deák B; Várady E; Tóth E; Csomor J; Matolcsy A; Lovey J; Lengyel Z; Petri K; Gaudi I; Rosta A
Orv Hetil; 2009 Nov; 150(44):2019-26. PubMed ID: 19861288
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
[TBL] [Abstract][Full Text] [Related]
20. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.
Kim SJ; Hong JS; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Kim YS; Yun HJ; Lee SI; Kim MK; Park EK; Kim WS; Suh C
Oncotarget; 2016 Nov; 7(44):72033-72043. PubMed ID: 27713132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]